Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
Nikolaos A. Patsopoulos(Broad Institute), Efthimios Dardiotis(University of Thessaly), Isabelle Cournu‐Rebeix, Allison Robbins, An Goris(University of Cambridge), Maria Cimpean, Sergio E. Baranzini(University of California, San Francisco), Henrik Ullum(Statens Serum Institut), Achim Berthele, Cristin McCabe, Benjamin Knier(Evangelisches Diakoniekrankenhaus), Brendan T Keenan(University of Pennsylvania), Bernhard Hemmer(Munich Cluster for Systems Neurology), Sandra Vukusic(Université Claude Bernard Lyon 1), Aaron Brandes(Broad Institute), Mark Mühlau(Technical University of Munich), Ioannis S. Vlachos(Broad Institute), Verena Grummel(Tampere University), Ashley Beecham, Lise Wegner Thørner, Felix Luessi, Viola Pongratz, Phoebe A. Winn, Bertrand Fontaine(Institut du Cerveau), Thomas Korn(TUM Klinikum), Christiane Graetz(Johannes Gutenberg University Mainz), Tune H. Pers(Novo Nordisk Foundation), Muni Hoshi, Janna Saarela(University of Helsinki), Till F. M. Andlauer(TUM Klinikum), Christiane Gasperi, Tojo James, Frauke Zipp(Johannes Gutenberg University Mainz), Vincent Damotte, Helle Bach Søndergaard, Joseph M. Replogle(Howard Hughes Medical Institute), Adam Santaniello(University of California, San Francisco), Onigiusz Zarzycki, Parisa Shoostari, Ioannis-Pavlos Panteliadis, Chris Cotsapas(Yale University), Bénédicte Dubois(University of California, San Francisco), Léna Guillot‐Noël(Centre National de la Recherche Scientifique), Per Soelberg Sorensen, Charles C. White(Boston University), Dorothea Buck, Mark Lathrop(McGill Genome Centre), Christina M. Lill(University of Münster), Garrett Wong, Finn Sellebjerg(Kaiser Permanente)
Cited by 1,426
Related Papers
New insights into the genetic etiology of Alzheimer’s disease and related dementias
|Nature Genetics|2022|2.5k
Analysis of shared heritability in common disorders of the brain
|Science|2018|2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
|New England Journal of Medicine|2016|1.9k
Multiple sclerosis
|The Lancet|2018|1.8k